Susquehanna Fundamental Investments LLC Boosts Holdings in Prothena Co. plc (NASDAQ:PRTA)

Susquehanna Fundamental Investments LLC increased its holdings in Prothena Co. plc (NASDAQ:PRTA) by 5.1% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,150 shares of the biotechnology company’s stock after purchasing an additional 1,470 shares during the period. Susquehanna Fundamental Investments LLC’s holdings in Prothena were worth $1,550,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Price T Rowe Associates Inc. MD lifted its holdings in Prothena by 22,878.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,312,346 shares of the biotechnology company’s stock worth $83,206,000 after purchasing an additional 3,297,931 shares in the last quarter. First Light Asset Management LLC lifted its holdings in Prothena by 42.8% in the 1st quarter. First Light Asset Management LLC now owns 2,935,707 shares of the biotechnology company’s stock worth $73,745,000 after purchasing an additional 879,254 shares in the last quarter. Redmile Group LLC purchased a new position in Prothena in the 1st quarter worth approximately $46,650,000. Palo Alto Investors LP lifted its holdings in Prothena by 3.0% in the 1st quarter. Palo Alto Investors LP now owns 1,742,505 shares of the biotechnology company’s stock worth $43,772,000 after purchasing an additional 50,700 shares in the last quarter. Finally, Rock Springs Capital Management LP lifted its holdings in Prothena by 1.4% in the 1st quarter. Rock Springs Capital Management LP now owns 1,156,900 shares of the biotechnology company’s stock worth $29,061,000 after purchasing an additional 15,800 shares in the last quarter. 91.43% of the stock is currently owned by institutional investors.

In other Prothena news, Director Christopher S. Henney sold 11,108 shares of the company’s stock in a transaction on Wednesday, July 14th. The stock was sold at an average price of $55.46, for a total value of $616,049.68. Following the transaction, the director now owns 11,108 shares of the company’s stock, valued at approximately $616,049.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Dennis J. Selkoe sold 5,000 shares of the company’s stock in a transaction on Friday, July 30th. The shares were sold at an average price of $49.47, for a total value of $247,350.00. Following the completion of the transaction, the director now directly owns 6,345 shares in the company, valued at approximately $313,887.15. The disclosure for this sale can be found here. Insiders sold a total of 40,000 shares of company stock worth $2,189,645 in the last ninety days. 30.40% of the stock is currently owned by corporate insiders.

NASDAQ PRTA opened at $75.32 on Friday. The company has a market cap of $3.33 billion, a P/E ratio of -40.28, a P/E/G ratio of 22.64 and a beta of 1.50. The business’s 50 day moving average price is $63.21 and its 200-day moving average price is $43.37. Prothena Co. plc has a fifty-two week low of $9.67 and a fifty-two week high of $78.95.

Prothena (NASDAQ:PRTA) last released its earnings results on Thursday, August 5th. The biotechnology company reported $0.58 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.56 by $0.02. Prothena had a negative return on equity of 30.73% and a negative net margin of 115.87%. On average, research analysts expect that Prothena Co. plc will post 1.45 EPS for the current fiscal year.

A number of research analysts recently commented on PRTA shares. Royal Bank of Canada boosted their price target on Prothena from $50.00 to $59.00 and gave the stock an “outperform” rating in a report on Monday, July 19th. Oppenheimer upped their price objective on Prothena from $82.00 to $90.00 and gave the stock an “outperform” rating in a report on Tuesday, September 14th. HC Wainwright upped their price objective on Prothena from $58.00 to $75.00 and gave the stock a “buy” rating in a report on Tuesday, July 13th. BTIG Research upped their price objective on Prothena from $29.00 to $65.00 and gave the stock a “buy” rating in a report on Friday, June 25th. Finally, Fox-Davies Capital initiated coverage on Prothena in a report on Monday, September 20th. They set an “overweight” rating and a $14.00 price objective on the stock. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $61.36.

Prothena Company Profile

Prothena Corp. Plc is a clinical-stage neuroscience company. It focuses on the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases.

Further Reading: Liquidity

Want to see what other hedge funds are holding PRTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prothena Co. plc (NASDAQ:PRTA).

Institutional Ownership by Quarter for Prothena (NASDAQ:PRTA)

Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.